Natural Health Trends Corp. (NHTC) Q3 2024 Earnings Call Transcript Summary
Natural Health Trends Corp. (NHTC) Q3 2024 Earnings Call Transcript Summary
Operating loss improved sequentially over three quarters, recording $275,000 this quarter.The following is a summary of the Natural Health Trends Corp. (NHTC) Q3 2024 Earnings Call Transcript:
以下是自然健康趨勢公司（NHTC）2024年第三季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Q3 2024 revenue was $10.7 million, marking a 1% increase year-over-year.
Gross profit margin declined to 74.1% from 74.7% due to higher costs associated with Premium Noni Juice.
Operating loss improved sequentially over three quarters, recording $275,000 this quarter.
Net income amounted to $35,000, or breakeven per diluted share.
2024年第三季度收入爲1,070萬美元，同比增長1％。
由於與優質諾麗果汁相關的成本上漲，毛利率從74.7％下降至74.1％。
營業虧損在三個季度中連續改善，本季度錄得27.5萬美元。
淨收益爲35,000美元，攤薄後每股盈虧平衡。
Business Progress:
業務進展：
Expanded into the Colombian market, officially opening on October 1.
Announced the introduction of new products such as Skindulgence revitalizing serum, eye cream, and other health supplements.
Continues to invest in digital enhancements expected to enhance member productivity and sales experience, set to launch early next year.
擴展到哥倫比亞市場，於10月1日正式開放。
宣佈推出新產品，例如Skindulgence活膚精華、眼霜和其他健康補品。
繼續投資於定於明年初推出的數字增強功能，預計將提高會員的生產力和銷售體驗。
Opportunities:
機會：
Market expansion through opening in Colombia and broad potential across Latin America.
Product innovation with new health supplements and personal care products.
Continued investment in digital tools to improve the selling and shopping experience.
通過在哥倫比亞的開放和拉丁美洲的廣泛潛力來擴大市場。
通過新的保健品和個人護理產品進行產品創新。
繼續投資數字工具，以改善銷售和購物體驗。
Risks:
風險：
Active member base decreased by 11% year-over-year, which may impact future revenue and sales.
活躍會員人數同比下降11％，這可能會影響未來的收入和銷售。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
